We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Glow-in-the-Dark Mice Used to Track Aging, Cancer in Real-Time

By LabMedica International staff writers
Posted on 29 Jan 2013
Scientists have developed a strain of mice that activates a gene from fireflies when the normal p16 gene is switched on.

In a study published in the January 18, 2013, issue of the journal Cell, researchers from the University of North Carolina (UNC) Lineberger Comprehensive Cancer Center (Chapel Hill, NC, USA) have developed a new way to visualize aging and tumor growth in mice using a gene closely associated to these mechanisms.

Researchers have known for quite a while that the gene, p16INK4a (p16), plays a role in aging and cancer inhibition by triggering an important tumor defense mechanism called cellular senescence. More...
The UNC team led by Norman Sharpless, MD, a professor of cancer research and deputy Cancer center director, has developed a strain of mice that turns on a gene from fireflies when the normal p16 gene is activated. In cells undergoing senescence, the p16 gene is switched on, activating the firefly gene and causing the affected tissue to glow.

Throughout the total lifespan of these mice, the researchers tracked p16 activation by just monitoring the brightness of each animal. They found that old mice are brighter than young mice, and that sites of cancer formation become extremely bright, allowing for the early identification of developing cancers. “With these mice, we can visualize in real time the activation of cellular senescence, which prevents cancer but causes aging. We can literally see the earliest molecular stages of cancer and aging in living mice,” said Dr. Sharpless.

The researchers foresee instantaneous practical uses for these glow-in-the-dark mice. By providing a visual signal of the activation cellular senescence, the mice will allow researchers to evaluate compounds and exposures that promote cellular aging (gerontogen testing) in the same manner that other mouse models currently allow toxicologists to identify cancer-causing substances (carcinogen testing). Moreover, these mice are already being used by scientists at UNC and other institutions to detect early cancer development and the response of tumors to anticancer treatments.

“This work builds on previous work by the same group, as well as others, showing intriguing relationships among aging, cancer and cell senescence. It provides a valuable new tool to probe these relationships,” said Felipe Sierra, PhD, director of the Division of Aging Biology, National Institute on Aging, the National Institutes of Health (NIH; Bethesda, MD, USA).

The researchers used these mice to make several unexpected discoveries. First, the group was able to track the accumulation of senescent cells in aging mice by assessing how brightly each mouse glowed. Amazingly, the brightest animals were no more apt to die from spontaneous cancer than the less bright animals of the same age. Meaning, the number of senescent cells in the mouse did not predict its risk of dying. “The result we—and I think others—predicted is that the animals with the highest number of senescent cells would get more cancers and die sooner, but this was not the case,” said Dr. Sharpless.

Another surprise came from the discrepancies in p16 levels among the mice. The scientists examined a large group of genetically identical animals that were all kept in the same way and fed the same diet. However, in spite of the same genetic and environmental environment, the brightness of individual mice at any given age was highly variable, suggesting that factors beyond genetics and diet influence aging.

The glowing mice also provide clues into cancer formation. Expression of p16 is activated in the earliest phases of cancer formation to inhibit cancer. Usually, activation of p16 suppresses cancer, but very rarely does this tumor-suppressor process fail and tumors develop, while still triggering the p16 gene. Thus, all tumors forming in these mice strongly glowed, allowing researchers to monitor early tumor formation in a wide variety of cancer types. In contrast to expectations, the researchers also discovered that p16 was triggered not only in the tumor cells themselves, but also in healthy, neighboring cells.

“This finding suggests that activation of senescence results from an abnormal milieu within a developing cancer. Somehow, many or all the cells in a would-be tumor know they are in a bad place, and activate this tumor suppressor gene as a defense mechanism, even if they are not the would-be cancer cells themselves. This occurs really early in the cancer; we’re talking about the earliest events of neoplasia that have ever been measured in living animals,” said Dr. Sharpless.

The scientists think that similar applications to monitoring senescence can be designed to examine tumor and aging development in humans. The group is particularly interested in how cancer therapies influence human aging and patient outcome. Working with UNC oncologists, the investigators have already gauged p16 expression in several hundred patients undergoing cancer therapy. These studies, combined with research utilizing the luminescent mice, should develop more effective and tolerable patient treatment strategies based upon “molecular,” as opposed to “chronologic,” age.

Related Links:

University of North Carolina Lineberger Comprehensive Cancer Center




Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Epstein-Barr Virus Test
Mononucleosis Rapid Test
New
Cytomegalovirus Test
NovaLisa Cytomegalovirus (CMV) IgG Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.